OncoMatch/Clinical Trials/NCT06424665
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
Is NCT06424665 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies FZ-AD005 for advanced solid tumor, sclc(small cell lung cancer) or lcnec (large cell neuroendocrine carcinoma).
Treatment: FZ-AD005 — A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Neuroendocrine Tumor
Tumor Agnostic
Disease stage
Metastatic disease required
advanced solid tumors ( especially SCLC or LCNEC); Have measurable lesions defined in RECIST v. 1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-DLL3 antibody
previous treatment with any anti-DLL3 antibody
Cannot have received: other anti-tumor treatments
receiving other anti-tumor treatments within 4 weeks prior to the first dose
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify